Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw

World Journal of Gastroenterology

Volumn 11, Issue 9, 2005, Pages 1339-1344

  Dong, Hui ^a   Lu, Fu Er ^a   Gao, Zhi Qiang ^a   Xu, Li Jun ^a   Wang, Kai Fu ^a   Zou, Xin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Emodin; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; EMODIN; GLUCOSE; INSULIN; LIPID; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET THERAPY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FLUID INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 15844397260     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i9.1339     Document Type: Article

References (34)

1. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80
2. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714-1719
3. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc-Cullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419
5. Dong H, Lu FE, Gao ZQ, Xu LJ, Wang KF, Zou X. Effects of emodin on murine fatty liver induced by feeding with alcohol and high fat laboratory chaw. Zhongguo Yiyuanyaoxue Zazhi 2005; (accepted and Epub ahead of print)
6. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82: 650-654
7. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95: 1056-1062
8. Kanauchi M. A new index of insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care 2002; 25: 1891-1892
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
10. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104
11. Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, Avila MA, Kanel G, Mato JM. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA 2001; 98: 5560-5565
12. Fan JG, Xu ZJ, Wang GL, Ding XD, Tian LY, Zheng XY. Change of serum endotoxin level in the progress of nonalcoholic steatohepatitis in rats. Zhonghua Ganzangbing Zazhi 2003; 11: 73-76
13. Zhu HJ, Shi YF, Hu MM, Jiang YX, Tan L, Liu YP. The effects of weight reduction in reversing fatty liver changes in overweight and obese patients. Zhonghua Neike Zazhi 2003; 42: 98-102
14. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226
15. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229
16. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413
17. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: A reversible condition. Acta Med Scand 1986; 220: 83-88
18. Fan JG, Zhong L, Xu ZJ, Tian LY, Ding XD, Li MS, Wang GL. Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 2003; 9: 2045-2049
19. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384
20. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000; 136: 734-738
21. Oliveira CP, Gayotto LC, Tatai C, Nina BI, Lima ES, Abdalla DS, Lopasso FP, Laurindo FR, Carrilho FJ. Vitamin C and E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr J 2003; 2: 9-13
22. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894
23. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-1467
24. Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol 2001; 96: 2711-2717
25. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-525
26. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 wk of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-1017
27. Srinivas G, Anto RJ, Srinivas P, Vidhyalakshmi S, Senan VP, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly (ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol 2003; 473: 117-125
28. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64: 519-533
29. Zhan Y, Li D, Wei H. Effect of emodin on development of hepatic fibrosis in rats. Zhongguo Zhongxiyjiehe Zazhi 2000; 20: 276-278
30. Day CP, James OF. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114: 842-845
31. Han J, Hajjar DP, Zhou X, Gotto AM Jr, Nicholson AC. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem 2002; 277: 23582-235866
32. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-196
33. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923
34. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455